Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$4.20B	0.43	3.66 million shs	3.84 million shs
AKRO Akero Therapeutics	$52.08 -4.1%	$50.63	$21.34 ▼ $58.40	$4.15B	-0.15	1.05 million shs	881,281 shs
KRYS Krystal Biotech	$147.49 -1.8%	$136.57	$122.80 ▼ $219.34	$4.34B	0.67	287,068 shs	303,976 shs
PROK ProKidney	$3.15 -10.5%	$1.33	$0.46 ▼ $7.13	$1.03B	1.26	3.61 million shs	6.55 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-4.89%	-9.62%	-7.72%	-21.49%	+25.88%
AKRO Akero Therapeutics	-4.14%	+0.99%	-5.14%	+38.40%	+92.32%
KRYS Krystal Biotech	-1.77%	-0.46%	+11.66%	-12.51%	-28.85%
PROK ProKidney	-10.51%	-30.62%	+352.39%	+298.28%	+36.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8701 of 5 stars	3.7	1.0	0.0	2.8	2.5	3.1
AKRO Akero Therapeutics	3.6516 of 5 stars	3.5	1.0	4.7	2.6	0.8	0.0
KRYS Krystal Biotech	4.538 of 5 stars	3.5	1.0	4.7	2.1	3.3	1.9
PROK ProKidney	3.5427 of 5 stars	3.2	4.0	0.0	3.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	58.41% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	44.93% Upside
PROK ProKidney	2.40	Hold	$6.25	98.41% Upside

Current Analyst Ratings Breakdown

Latest PROK, KRYS, AKRO, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.37	$0.51 per share	32.50	$1.48 per share	11.30
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
KRYS Krystal Biotech	$333.45M	12.78	$4.55 per share	32.38	$32.90 per share	4.48
PROK ProKidney	$80K	11,525.06	N/A	N/A	($3.41) per share	-0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	19.68	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	35.45	14.63	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest PROK, KRYS, AKRO, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	PROK ProKidney	-$0.14	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
AKRO Akero Therapeutics	0.03	16.80	16.80
KRYS Krystal Biotech	N/A	9.65	9.27
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
KRYS Krystal Biotech	86.29%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AKRO Akero Therapeutics	7.07%
KRYS Krystal Biotech	13.70%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

PROK, KRYS, AKRO, and ADMA Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?

July 18 at 12:35 PM | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Receives $5.67 Average Price Target from Analysts

July 18 at 2:23 AM | americanbankingnews.com

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 17 at 1:01 PM | zacks.com

Best Momentum Stocks to Buy for July 17th

July 17 at 11:01 AM | zacks.com

New Strong Buy Stocks for July 17th

July 17 at 6:40 AM | zacks.com

ProKidney gains pivotal therapy advancement step with FDA

July 17 at 6:15 AM | journalnow.comJ

ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?

July 16 at 1:01 PM | zacks.com

ProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst Upgrade

July 16 at 2:18 AM | americanbankingnews.com

ProKidney (NASDAQ:PROK) Shares Gap Up on Analyst Upgrade

July 16 at 2:27 AM | americanbankingnews.com

Promising clinical trial results give ProKidney share price major boost

July 15, 2025 | journalnow.comJ

ProKidney stock soars after FDA confirms accelerated approval pathway

July 15, 2025 | in.investing.com

ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial

July 15, 2025 | marketwatch.com

ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy

July 15, 2025 | msn.com

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst Upgrade

July 15, 2025 | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from Brokerages

July 15, 2025 | marketbeat.com

ProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and Diabetes

July 15, 2025 | quiverquant.comQ

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15, 2025 | globenewswire.com

ProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst Upgrade

July 14, 2025 | marketbeat.com

Guggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00

July 14, 2025 | marketbeat.com

Promising clincial trial results give ProKidney share price major boost

July 14, 2025 | greensboro.comG

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, KRYS, AKRO, and ADMA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07/18/2025 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$52.08 -2.25 (-4.14%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$52.74 +0.66 (+1.27%)

As of 07/18/2025 07:33 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$147.49 -2.66 (-1.77%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$147.40 -0.09 (-0.06%)

As of 07/18/2025 07:50 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

ProKidney NASDAQ:PROK

$3.15 -0.37 (-10.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.04 (+1.43%)

As of 07/18/2025 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time